FDA Gives Nod To 1st Sinusitis Drug That Includes Nasal Polyps

ANDREW BARNES | July 3, 2019

article image
In what specialists have termed to a pivotal point, the FDA approved a chronic sinusitis drug, a disease which causes polyps in the sinuses. Names Dupixent, the injection is administered every 2 weeks. Those with chronic rhinosinusitis and nasal polyps will be treated with this drug. FDA stated that nasal polyps cause damage to smell abilities and require surgery for treatment. Dupixent is termed to provide treatment alternatives for those whose polyps can’t be controlled via intranasal steroids. This decreases the requirement for oral steroids and polyp surgery. Specialists have applauded this move.

Spotlight

CAE Healthcare

CAE Healthcare: Providing solutions for simulation-based medical education (SBME) that improve healthcare, clinical competency, and patient CAE Healthcare delivers advanced, state-of-the-art simulation-based training that enables healthcare professionals to provide safer, high-quality care. Our end-to-end spectrum of solutions include patient, imaging, interventional and surgical simulation, audiovisual solutions, learning applications, and center management programs to drive the future of innovation in training for the benefit of patients and healthcare providers the world over.

OTHER ARTICLES

What to Watch in 2020: Non-Specialty Drugs

Article | March 1, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

Clinical Supply Availability & Speed to Study Start-Up

Article | March 1, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | March 1, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More
PHARMACY MARKET

A pharma outsourcing mission

Article | March 1, 2020

In a way, getting through the initial stages of a complex pharmaceutical project that is being outsourced to a contract development and manufacturing organization is like getting a rocket off the ground. Many drug developers express frustration with the time it often takes during the initial stages of working with a CDMO — from the time they first reach out to a CDMO for help until they receive a proposal. Some have described it as months of silence from when they send a request for proposal (RFP) until they have a proposal in hand. The initial stages of a relationship between drug sponsor and CDMO often do not get the attention it deserves, and valuable time is lost, delaying projects and delaying delivery of therapeutics to patients. The quick scheduling of the ACT meeting with the right attendees can deliver immediate answers to key questions needed by the drug sponsor for effective planning and can help propel projects to a successful launch.

Read More

Spotlight

CAE Healthcare

CAE Healthcare: Providing solutions for simulation-based medical education (SBME) that improve healthcare, clinical competency, and patient CAE Healthcare delivers advanced, state-of-the-art simulation-based training that enables healthcare professionals to provide safer, high-quality care. Our end-to-end spectrum of solutions include patient, imaging, interventional and surgical simulation, audiovisual solutions, learning applications, and center management programs to drive the future of innovation in training for the benefit of patients and healthcare providers the world over.

Events